What MEnD-AKI Revealed About AI Alerts, With Sandra Kane-Gill, PharmD, MS Sandra Kane-Gill, PharmD, MS

Published Date: 25 Oct 2026

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Read Full News

Latest News

Robotics and Organ Preservation in Transplant, With Ari Cohen, MD Ari Cohen, MD, MBA

An Ochsner transplant surgeon discusses 10,000 transplants and how new tools are expanding who can receive an organ.

Atacicept Slows IgAN Decline to Physiologic Rate, With Sayna Norouzi, MD Sayna Norouzi, MD

Final ORIGIN 3 analysis shows a 76% lower risk of kidney disease progression vs placebo through 2 years.

Ochsner Health Expands Liver Transplant Access Through Multidisciplinary Care Ari Cohen, MD, MBA

Ochsner Health uses multidisciplinary clinics, living donor programs, and transplant innovations to address access challenges.

How Glomerular Disease Shapes Young Women's Life Choices, With Sayna Norouzi, MD Sayna Norouzi, MD

An AHA statement co-author says reproductive and family planning concerns belong in kidney care for women with glomerular disease.

Pregnancy After Living Kidney Donation, With Amit X. Garg, MD, PhD Amit X. Garg, MD, PhD

Amit X. Garg, MD, PhD, discusses new JAMA data on preeclampsia risk after living kidney donation in a 3-part video interview.

Felzartamab and the Hidden Injury of Isolated MVI, With Yasir Qazi, MD Yasir Qazi, MD

TRANSPIRE investigator Yasir Qazi, MD, explains how isolated MVI can signal kidney transplant injury before creatinine rises.

Todays Updates

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage Marco Meglio

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Marco Meglio

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

Why PAD Goes Undetected in Advanced CKD, With Pranav Garimella, MBBS, MPH Pranav Garimella, MBBS, MPH

Calcified vessels may mask PAD on ankle brachial index testing, and Garimella says nephrologists can help catch it earlier.

AI Alerts Did Not Reduce Kidney Events, With Sandra Kane-Gill, PharmD, MS Sandra Kane-Gill, PharmD, MS

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D Phoom Narongkiatikhun, MD

Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D.

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Todays Updates

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage Marco Meglio

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Marco Meglio

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

Why PAD Goes Undetected in Advanced CKD, With Pranav Garimella, MBBS, MPH Pranav Garimella, MBBS, MPH

Calcified vessels may mask PAD on ankle brachial index testing, and Garimella says nephrologists can help catch it earlier.

AI Alerts Did Not Reduce Kidney Events, With Sandra Kane-Gill, PharmD, MS Sandra Kane-Gill, PharmD, MS

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D Phoom Narongkiatikhun, MD

Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D.

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Latest News

An Ochsner transplant surgeon discusses 10,000 transplants and how new tools are expanding who can receive an organ.

Final ORIGIN 3 analysis shows a 76% lower risk of kidney disease progression vs placebo through 2 years.

Ochsner Health uses multidisciplinary clinics, living donor programs, and transplant innovations to address access challenges.

An AHA statement co-author says reproductive and family planning concerns belong in kidney care for women with glomerular disease.

Amit X. Garg, MD, PhD, discusses new JAMA data on preeclampsia risk after living kidney donation in a 3-part video interview.

TRANSPIRE investigator Yasir Qazi, MD, explains how isolated MVI can signal kidney transplant injury before creatinine rises.

News All Time

ASN Kidney Week 2026 Preview: 8 Late-Breakers We’ll Unpack With the Investigators

Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.

Lack of CKD Awareness Limits GLP-1 RA Kidney Protection in Over 9 Million US Adults

Lack of CKD Awareness Limits GLP-1 RA Kidney Protection in Over 9 Million US Adults

Iptacopan Maintains Kidney Benefit Through 48 Months in IgA Nephropathy

Iptacopan Maintains Kidney Benefit Through 48 Months in IgA Nephropathy

Mezagitamab, an anti-CD38 Monoclonal Antibody, Stabilizes eGFR 18 months Off Treatment in IgAN Patrick Campbell

Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.

Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY Abigail Brooks, MA

Final VISIONARY data show sibeprenlimab held eGFR steady over 24 months, with a 4.5 mL/min/1.73 m² per year slope advantage and fewer kidney outcome events vs placebo.

Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy

Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy

Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD

Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD

10 Nephrology Headlines You Missed in Q3 2026

10 Nephrology Headlines You Missed in Q3 2026

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD Gaia Coppock, MD

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

What's Still Missing in IgA Nephropathy Care, With Brad Rovin, MD Brad Rovin, MD

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

Bioengineered Vessel Increases Catheter-Free Time in Women on Dialysis Mohamad Hussain, MD, PhD

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

Recommended News For You

Researchers publish action plan to address appendiceal cancer enigmas

Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

Kekoa Taparra, a native Hawaiian physician-scientist, is becoming well-known.

Guideline on management of early-stage non-small cell lung cancer released

Recommended Articles For You

Hematopoietic Niche Exhaustion in Age-Related Blood Disorders 

Hematologic Fatigue and Work Function: Clinical Implications, Pathophysiology, and Management 

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring 

Iron Deficiency Anemia: Modern Diagnostic Approaches and Personalized Treatment Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

2.

Hypnotherapy may offer real benefits for cancer patient care

3.

Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer

4.

From Pathology to Precision: The Story of Leukemia Therapy

5.

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

1.

The Benefits of Understanding Haptoglobin High: What You Need to Know

2.

Hemophilia: Pathophysiology, Genetics, and Treatment Advances

3.

Immune Niches Supporting Tumor Resistance: Mechanisms, Clinical Implications, and Emerging Therapies

4.

Tumor Dormancy Dynamics and Recurrence-Free Survival Patterns

5.

Radiomics-Based Prediction of Treatment Response in Cancer

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot